Dicerna Pharmaceuticals, Inc. (DRNA) Posts Q1 Loss of $1.02/Share

Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA) reported Q1 EPS of ($1.02), $0.50 worse than the analyst estimate of ($0.52).

For earnings history and earnings-related data on Dicerna Pharmaceuticals, Inc. (DRNA) click here.

You May Also Be Interested In

• JPMorgan Upgrades Aviva Plc (AV/:LN) (AIVAF) to Overweight
• Goldman Sachs Upgrades Tingyi Cayman Islands Holding Corp. (322:HK) (TCYMY) to Buy
• Morgan Stanley Upgrades Oil India Ltd. (OINL:IN) to Equalweight